Beyond Restenosis: Five-Year Clinical Outcomes From Second-Generation Coronary Stent Trials
暂无分享,去创建一个
D. Baim | J. Massaro | D. Cohen | D. Cutlip | K. Ho | R. Kuntz | A. Bakhai | M. Chauhan | S. Marulkar | Amit Chhabra | D. Cohen | D. Cohen
[1] Jeffrey W Moses,et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.
[2] D. Baim,et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. , 2002, Journal of the American College of Cardiology.
[3] Eric J Topol,et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[4] S. Ellis,et al. Emergency Coronary Artery Bypass Surgery in the Contemporary Percutaneous Coronary Intervention Era , 2002, Circulation.
[5] P. Serruys,et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[6] M. Nobuyoshi,et al. Long-Term Clinical and Angiographic Follow-Up After Coronary Stent Placement in Native Coronary Arteries , 2002, Circulation.
[7] W Rutsch,et al. Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial. , 2001, Journal of the American College of Cardiology.
[8] D. Baim,et al. Stent Thrombosis in the Modern Era: A Pooled Analysis of Multicenter Coronary Stent Clinical Trials , 2001, Circulation.
[9] The Esprit investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial , 2000, The Lancet.
[10] R. Califf,et al. Predictors of mortality and mortality from cardiac causes in the bypass angioplasty revascularization investigation (BARI) randomized trial and registry. For the BARI Investigators. , 2000, Circulation.
[11] S. Kleinert. HOPE for cardiovascular disease prevention with ACE-inhibitor ramipril , 1999, The Lancet.
[12] T. Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. , 1998, Lancet.
[13] R. Califf,et al. Myonecrosis after revascularization procedures. , 1998, Journal of the American College of Cardiology.
[14] M. Hadamitzky,et al. Predictive factors of restenosis after coronary stent placement. , 1997, Journal of the American College of Cardiology.
[15] D. Baim,et al. Long-term (4- to 6-year) outcome of Palmaz-Schatz stenting: paucity of late clinical stent-related problems. , 1996, Journal of the American College of Cardiology.
[16] Ousa,et al. A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .
[17] R. Califf,et al. Predictors of Mortality and Mortality From Cardiac Causes in the Bypass Angioplasty Revascularization Investigation (BARI) Randomized Trial and Registry , 2000 .
[18] V. Paul,et al. Recruited collateral channels are not responsible for ischemic preconditioning during single vessel angioplasty , 1998 .